Dermatomycoses - Pipeline Review, H1 2016

  • ID: 3766778
  • Drug Pipelines
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Helix BioMedix, Inc.
  • TGV-Laboratories
  • MORE
Dermatomycoses - Pipeline Review, H1 2016

Summary

The report ‘Dermatomycoses - Pipeline Review, H1 2016’, provides an overview of the Dermatomycoses pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dermatomycoses
- The report reviews pipeline therapeutics for Dermatomycoses by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dermatomycoses therapeutics and enlists all their major and minor projects
- The report assesses Dermatomycoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dermatomycoses

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dermatomycoses
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dermatomycoses pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Helix BioMedix, Inc.
  • TGV-Laboratories
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Dermatomycoses Overview

Therapeutics Development

Pipeline Products for Dermatomycoses - Overview

Pipeline Products for Dermatomycoses - Comparative Analysis

Dermatomycoses - Therapeutics under Development by Companies

Dermatomycoses - Therapeutics under Investigation by Universities/Institutes

Dermatomycoses - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Dermatomycoses - Products under Development by Companies

Dermatomycoses - Products under Investigation by Universities/Institutes

Dermatomycoses - Companies Involved in Therapeutics Development

Anacor Pharmaceuticals, Inc.

Blueberry Therapeutics Ltd

Daewoong Pharmaceutical Co., Ltd.

Helix BioMedix, Inc.

TGV-Laboratories

Viamet Pharmaceuticals, Inc.

Dermatomycoses - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AN-2718 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BB-2603 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dapaconazole - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DWP-06081 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HB-1275 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Myc-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Fungal Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VT-1161 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dermatomycoses - Recent Pipeline Updates

Dermatomycoses - Dormant Projects

Dermatomycoses - Product Development Milestones

Featured News & Press Releases

Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis

Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dermatomycoses, H1 2016

Number of Products under Development for Dermatomycoses - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Dermatomycoses - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016

Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H1 2016

Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016

Dermatomycoses - Pipeline by Helix BioMedix, Inc., H1 2016

Dermatomycoses - Pipeline by TGV-Laboratories, H1 2016

Dermatomycoses - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Dermatomycoses Therapeutics - Recent Pipeline Updates, H1 2016

Dermatomycoses - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Dermatomycoses, H1 2016

Number of Products under Development for Dermatomycoses - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Anacor Pharmaceuticals, Inc.
Blueberry Therapeutics Ltd
Daewoong Pharmaceutical Co., Ltd.
Helix BioMedix, Inc.
TGV-Laboratories
Viamet Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll